Clinical features | Survivals (n = 196) | Cardiac deaths (n = 12) |
---|---|---|
Study characteristics | ||
Follow-up (months) | 27.99 ± 6.02 | 11.17 ± 10.85 |
Patient characteristics | ||
Age (years) | 60.19 ± 11.39 | 71.83 ± 7.29* |
Sex (female) | 52 (27%) | 6 (50%)* |
LVEF | 54.86 ± 11.18 | 46.00 ± 11.15* |
LVEF < 0.35 | 9 (4.6%) | 3 (25%)* |
Smoking (ex or current) | 110 (56%) | 4 (33%)* |
Diabetes mellitus | 42 (21%) | 8 (67%)* |
Previous myocardial infarction | 25 (13%) | 2 (17%) |
Hypertension | 95 (48%) | 11 (92%)* |
Treatment | ||
PTCA | 117 (60%) | 7 (58%) |
Thrombolysis | 44 (22%) | 2 (17%) |
No acute revascularization | 35 (18%) | 3 (25%) |
Aspirin or clopidogrel | 194 (99%) | 12 (100%) |
β-blockers | 158 (81%) | 10 (83%) |
Statins | 192 (98%) | 10 (83%)* |
ACEI/ARB | 150 (77%) | 9 (75%) |
Diuretic | 134 (68%) | 7 (58%) |